WuXi XDC Cayman Inc., a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specialising in antibody-drug conjugates (ADCs) and other bioconjugates, has announced an out-licensing collaboration with Ona Therapeutics on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform. Ona Therapeutics is a global biotechnology company pioneering first-in-class ADCs to address treatment-resistant cancers.
Under the terms of the agreement, China-based WuXi XDC will grant Ona Therapeutics an exclusive global license to its proprietary WuXiTecan-2 payload-linker technology for the development of an ADC candidate against a single target.
Ona Therapeutics will combine its first-in-class target discovery capabilities with the WuXiTecan-2 platform. The total potential deal value includes an upfront payment, and certain development, regulatory, and sales milestone payments.
Additionally, WuXi XDC will be eligible to receive tiered royalties on net sales upon commercialisation of the resulting ADC product. WuXi XDC will provide comprehensive chemistry, manufacturing and controls (CMC) development and manufacturing support through its integrated ADC CRDMO platform.
This collaboration marks the second partnership between Ona Therapeutics and WuXi XDC in the ADC field.
